drugset

drugset / Trial / NCT04447573

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT04447573 ↗

Unknown 20 enrolled Hebei Senlang Biotechnology Inc., Ltd. Beijing Lu Daopei Hospital · collab Hebei Yanda Ludaopei Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma

Timeline

Start: 2020-06-30
Primary completion: 2022-08-30
Completion: 2022-12-30

Publications

Zhang XG, Wang L, Yang J, Hu XN, Wang H, Zhang LN, Zhou X, Liu Y, Wang Q, Lu PH. Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma. Blood Adv. 2025 Sep 23;9(18):4543-4552. doi: 10.1182/bloodadvances.2025016322.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BCMA CAR-T	Cell therapy	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—

Indications